219 related articles for article (PubMed ID: 33241721)
1. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
Goadsby PJ; Blumenfeld AM; Lipton RB; Dodick DW; Kalidas K; M Adams A; Jakate A; Liu C; Szegedi A; Trugman JM
Cephalalgia; 2021 Apr; 41(5):546-560. PubMed ID: 33241721
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
Hutchinson S; Silberstein SD; Blumenfeld AM; Lipton RB; Lu K; Yu SY; Severt L
Cephalalgia; 2021 Aug; 41(9):979-990. PubMed ID: 33874756
[TBL] [Abstract][Full Text] [Related]
3. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
Lipton RB; Dodick DW; Ailani J; Lu K; Finnegan M; Szegedi A; Trugman JM
JAMA; 2019 Nov; 322(19):1887-1898. PubMed ID: 31742631
[TBL] [Abstract][Full Text] [Related]
4. Ubrogepant for the Treatment of Migraine.
Dodick DW; Lipton RB; Ailani J; Lu K; Finnegan M; Trugman JM; Szegedi A
N Engl J Med; 2019 Dec; 381(23):2230-2241. PubMed ID: 31800988
[TBL] [Abstract][Full Text] [Related]
5. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Blumenfeld AM; Goadsby PJ; Dodick DW; Hutchinson S; Liu C; Finnegan M; Trugman JM; Szegedi A
Headache; 2021 Mar; 61(3):422-429. PubMed ID: 33749826
[TBL] [Abstract][Full Text] [Related]
7. Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials.
Hutchinson S; Dodick DW; Treppendahl C; Bennett NL; Yu SY; Guo H; Trugman JM
Neurol Ther; 2021 Jun; 10(1):235-249. PubMed ID: 33608814
[TBL] [Abstract][Full Text] [Related]
8. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.
Blumenfeld AM; Knievel K; Manack Adams A; Severt L; Butler M; Lai H; Dodick DW
Adv Ther; 2022 Jan; 39(1):692-705. PubMed ID: 34874514
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
[TBL] [Abstract][Full Text] [Related]
10. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials.
Lipton RB; Singh RBH; Revicki DA; Zhao S; Shewale AR; Lateiner JE; Dodick DW
J Headache Pain; 2022 Apr; 23(1):50. PubMed ID: 35468729
[TBL] [Abstract][Full Text] [Related]
11. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
Voss T; Lipton RB; Dodick DW; Dupre N; Ge JY; Bachman R; Assaid C; Aurora SK; Michelson D
Cephalalgia; 2016 Aug; 36(9):887-98. PubMed ID: 27269043
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795
[TBL] [Abstract][Full Text] [Related]
13. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
Polavieja P; Belger M; Venkata SK; Wilhelm S; Johansson E
J Headache Pain; 2022 Jul; 23(1):76. PubMed ID: 35790906
[TBL] [Abstract][Full Text] [Related]
14. Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.
Johnston KM; Powell L; Popoff E; Harris L; Croop R; Coric V; L'Italien G
Clin J Pain; 2022 Nov; 38(11):680-685. PubMed ID: 36125279
[TBL] [Abstract][Full Text] [Related]
15. Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
Nedd M; Garland S; Falk N; Wilk A
Ann Pharmacother; 2022 Mar; 56(3):346-351. PubMed ID: 34109839
[TBL] [Abstract][Full Text] [Related]
16. Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment.
Li CC; Voss T; Kowalski K; Yang B; Kleijn HJ; Jones CJ; Bosch R; Michelson D; DeAngelis M; Xu Y; Xie I; Kothare PA
Clin Transl Sci; 2020 May; 13(3):482-490. PubMed ID: 31758661
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.
Lipton RB; Dodick DW; Goadsby PJ; Burstein R; Adams AM; Lai J; Yu SY; Finnegan M; Kuang AW; Trugman JM
Neurology; 2022 Oct; 99(17):e1905-e1915. PubMed ID: 35977836
[TBL] [Abstract][Full Text] [Related]
18. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
[TBL] [Abstract][Full Text] [Related]
19. Ubrogepant to treat migraine.
Dhir A
Drugs Today (Barc); 2020 Jul; 56(7):459-467. PubMed ID: 32648856
[TBL] [Abstract][Full Text] [Related]
20. Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials.
Iaconangelo CJ; Serrano D; Adams AM; Trugman JM; Lipton RB
Headache; 2023; 63(10):1412-1422. PubMed ID: 37873925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
